Last reviewed · How we verify
Interferon Alfacon-1 and Ribavirin
At a glance
| Generic name | Interferon Alfacon-1 and Ribavirin |
|---|---|
| Sponsor | Beth Israel Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C (PHASE3)
- Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C
- Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial (PHASE3)
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C (PHASE2)
- Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C (PHASE3)
- Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (PHASE4)
- Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Interferon Alfacon-1 and Ribavirin CI brief — competitive landscape report
- Interferon Alfacon-1 and Ribavirin updates RSS · CI watch RSS
- Beth Israel Medical Center portfolio CI